comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 00:48:33 - browse：36521

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

WSS

Akero's treatment for NASH falls short in cirrhosis study

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

STAT Readout: Today's biotech news includes Sana and Amylyx

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

PBM reforms clear House panel

David Sabatini, ex

explore

comprehensive

focus

How to save PrEP access — and even expand it

Gain of function research would be limited under House proposal

23andMe had bad news about my health. I wish a person had delivered it

In key trial, Verve's treatment lowers cholesterol levels in patients

What does generative AI mean for health care? We asked experts

Nick Jonas talks about managing diabetes along with his career

Medicare proposal to cover medical devices draws a mixed reaction

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Jerome Adams on the need for new antivirals for Covid

STAT Readout: Today's biotech news includes Sana and Amylyx

focus

Medicare to cover more brain scans related to Alzheimer’s drugs

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Akero's treatment for NASH falls short in cirrhosis study

How clinical AI models' predictive power can degrade over time

Researchers CRISPR chickens in bid to protect them from bird flu

entertainment

explore

leisure time

Wikipedia